Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC

Wen-Chi L Chang1, Lynette C Everley, Gordon R Pfeiffer

  • 1Division of Population Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. wen-chi.chang@fccc.edu

Insights

Sulindac sulfone, a nonsteroidal anti-inflammatory drug metabolite, effectively reduces beta-catenin and related proteins in specific cancer cells. Its mechanism involves modulating the APC/beta-catenin pathway, depending on cellular mutations.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sulindac sulfone, a metabolite of sulindac, lacks cyclooxygenase activity but is known to inhibit tumorigenesis.
  • Its anti-cancer mechanism, often attributed to apoptosis induction, is not fully understood.
  • The adenomatous polyposis coli (APC)/beta-catenin pathway is crucial in colorectal cancer development.

Purpose of the Study:

  • To investigate the effect of sulindac metabolites on beta-catenin levels and the APC/beta-catenin pathway in vitro.
  • To compare the potency of sulindac sulfone and its sulfide metabolite in regulating this pathway.
  • To determine if sulindac sulfone's efficacy is dependent on the mutational status of APC and beta-catenin.

Main Methods:

  • Treatment of various colon cancer cell lines (SW480, HCA7, LS174, Caco-2) with sulindac metabolites.
  • Quantification of cellular levels of beta-catenin, pro-caspase 3, cyclin D1, and PPARdelta.
  • Assessment of TCF-mediated transcriptional activity.

Main Results:

  • Sulindac sulfone significantly decreased total cellular beta-catenin, pro-caspase 3, cyclin D1, and PPARdelta in SW480 cells.
  • These effects were more potent than those observed with the sulindac sulfide metabolite.
  • No significant changes in pro-caspase 3 or beta-catenin were observed in HCA7, LS174, or Caco-2 cells.
  • A dose-dependent reduction in TCF-mediated transcriptional activity was noted in SW480 cells.

Conclusions:

  • Sulindac sulfone can modulate the APC/beta-catenin pathway in vitro.
  • The compound's efficacy is contingent upon the specific mutational status of APC and beta-catenin within the cells.
  • These findings provide insights into the molecular mechanisms underlying sulindac sulfone's anti-cancer properties.

Related Concept Videos

Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...